Incidence, Prevalence, Disease Course, and Treatment Strategy of Crohn’s Disease Patients from the Veszprem Cohort, Western Hungary: A Population-based Inception Cohort Study Between 2007 and 2018

Author:

Gonczi Lorant1,Lakatos Laszlo2,Kurti Zsuzsanna1,Golovics Petra A3,Pandur Tunde4,David Gyula2,Erdelyi Zsuzsanna2,Szita Istvan2,Lakatos Peter L15ORCID

Affiliation:

1. Department of Internal Medicine and Oncology, Semmelweis University , Budapest , Hungary

2. Department of Gastroenterology, Ferenc Csolnoky Hospital , Veszprem , Hungary

3. Department of Gastroenterology, Hungarian Defence Forces Medical Centre , Budapest , Hungary

4. Department of Gastroenterology, Grof Eszterhazy Hospital , Papa , Hungary

5. Division of Gastroenterology, McGill University Health Center , Montreal, QC , Canada

Abstract

Abstract Background and Aims The number of prospective population-based studies on Crohn’s disease[CD] is still limited from Eastern Europe. The present study is a continuation of the Veszprem IBD cohort. Our aim was to analyse incidence, prevalence, disease phenotype, treatment strategy, disease course, and surgical outcomes in a prospective population-based inception cohort including CD patients diagnosed between 2007 and 2018. Methods A total of 421 consecutive inception patients were included [male/female:237/184; mean age at diagnosis: 33.3 ± 16.2years]. Both in-hospital and outpatient records were collected and comprehensively reviewed. Demographic data were derived from the Hungarian Central Statistical Office. Results Mean incidence rate was 9.9 [95% CI: 9.0-10.9]/105 person-years in this 12-year period. Prevalence rate was 236.8 [95% CI: 220.8-252.8] in 2015; 17.6% and 20.0% of the patients had stenosing[B2] and penetrating[B3] disease behavior at diagnosis,respectively. The probability of disease behaviour progression from luminal to B2/B3 phenotype was 14.7% (standard error [SE]: 2.2) at 5 years after diagnosis. Distribution of maximal therapeutic steps during the total follow-up (8.5 years [8.5y], standard deviation [SD]: 3.3) was 5-aminosalicylic acid [5-ASA] in 15.7%, corticosteroids in 14.3%, immunosuppressives in 42.5%, and biologic therapy in 26.2%. The probability of receiving biologictherapy after diagnosis was 20.9% [SE: 2.0] at 5 years. The probability of first resective surgery was 20.7% [SE: 2.0] at 1 year, 26.1% [SE: 2.2] at 5 years, and 30.7% [SE: 2.4] at 10 years. The perianal surgery rate was 31.3% among patients with perianal involvement. Conclusions The incidence of CD in Hungary was high, similar to high-incidence areas in Western Europe. Treatment strategies are reflecting the biologic era. Disease behaviour progression was lower, as well as long-term [10y] surgery rates decreasing compared with data from previous decades.

Funder

Ministry of Human Capacities, Hungary

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

Reference26 articles.

1. ECCO Thirdrd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016. Part 1: diagnosis and medical management;Gomollón;J Crohns Colitis.,2017

2. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences;Loftus;Gastroenterology.,2004

3. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies;Ng;Lancet,2017

4. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease [EC-IBD];Shivananda;Gut,1996

5. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006;Lakatos;Inflamm Bowel Dis,2011

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3